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ABSTRACT 
In many solid cancers, and also in colon adenocarcinomas, an increased accumulation of 
lymphocytes is beneficial for the patient. However, tumor-infiltrating immune cells may be 
either pro- or anti-tumorigenic and the balance between these two counteracting forces partly 
determines patient outcome. Boosting of the anti-tumor immune response by immunotherapy, 
e.g. by immune checkpoint blockade, has been highly successful in several types of cancer but 
less so for colon cancer. In the interest of developing new cancer immunotherapies also for the 
treatment of colon cancer, additional studies of tumor-infiltrating lymphocytes in colon cancer 
are warranted. In this study, we used flow cytometry and flow cytometric cell sorting as well as 
in vitro cell culture assays to examine the phenotype and effector functions of two distinct 
immune cell populations which we have shown to accumulate in tumors of colon cancer patients, 
CD39+ regulatory T cells (CD39+ Treg) and mucosal-associated invariant T (MAIT) cells. Treg 
reduce the activity of other immune cells and can express the surface molecule CD39, an 
ectoenzyme involved in converting extracellular ATP to immunosuppressive adenosine. MAIT 
cells recognize bacterial metabolites and are innate-like T cells which are believed to provide a 
first line defense at epithelial surfaces. This thesis comprises an extensive phenotypic and 
functional characterization of these two subsets in colon tumors, and also preliminary survival 
data on their respective impact on patient prognosis.  
We show that CD39+ Treg constitute a highly activated and immunosuppressive Treg subset. In 
particular, surface expression of immunomodulatory mediators were increased in the CD39+ 
Treg subset, while cytokine production was similar in CD39+ and CD39- Treg. We also present 
preliminary survival data which suggests a correlation between high levels of CD39 expression 
on intratumoral Treg and a worse patient prognosis, thus highlighting CD39+ Treg as a potential 
candidate for targeted immunotherapy. With regard to MAIT cells, we could demonstrate 
accumulation of MAIT cells in colon adenocarcinomas. However, there were reduced 
frequencies of IFN-g-producing cells among tumor-associated MAIT cells compared to MAIT 
cells from unaffected colon tissue. MAIT-cell infiltration into colon tumors has been correlated 
with poor patient prognosis and in an independent appendix of the thesis, we present preliminary 
data actually showing a positive impact of MAIT cell infiltration into colon tumors on patient 
survival.  
Keywords: colon cancer, regulatory T cells, CD39, adenosine, immune checkpoint molecules, 
immunosuppression, MAIT cells, cytokines, cancer-specific survival 
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SAMMANFATTNING PÅ SVENSKA 
Koloncancer orsakar årligen en omfattande cancerrelaterad död och det finns ett stort behov av 
utveckling av nya alternativa behandlingsstrategier inom området. Medan behandlingen av 
flertalet cancerformer, såsom avancerat malignt melanom, lungcancer och prostatacancer, har 
revolutionerats genom införandet av tilläggsbehandling i form av immunterapi med T-cells 
aktiverande antikroppar (immune checkpoint inhibitors), har koloncancer svarat sämre på den 
här behandlingsformen. Endast hypermuterade tumörer, som utgör en mindre andel av all 
koloncancer och karakteriseras av en förhållandevis hög grad av immuncellsinfiltration, har i 
detta sammanhanget uppvisat ett lovande behandlingssvar. T-cells aktiverande antikroppar 
verkar genom att blockera hämningen av T celler i tumören och närvaro av ett rikt 
immuncellsinfiltrat i tumören anses vara en förutsättning för ett bra behandlingssvar vid den här 
behandlingsformen. Ett rikt immuncellsinfiltrat i kolontumörer är även i sig självt förknippat 
med en fördelaktig patientprognos, tydligt visat när varje enskild kolontumör klassificeras enligt 
”Immunoscore”, ursprungligen definierat av Jerome Galón. I takt med en ökad kunskap om 
samspelet mellan tumörinfiltrerande immunceller i koloncancer och deras bidrag till 
tumörtillväxt, samt en ökad förståelse av T-cells aktiverande antikroppars verkningsmekanism 
och även andra alternativa immunterapier, finns en förhoppning om att en större andel av 
koloncancer ska svara på immunterapi inom en snar framtid.  
I den här avhandlingen har vi karaktäriserat och studerat funktionen hos två olika 
immuncellspopulationer som båda utgör en del av immuncellsinfiltratet i kolontumörer, i.e. 
regulatoriska T celler (Treg) som uttrycker enzymet CD39 på sin yta (CD39+ Treg) och mucosal-
associated invariant T (MAIT) celler. Båda de här celltyperna förekommer i såväl 
kolonslemhinnan hos friska individer som i kolontumörer. CD39 är delaktig i omvandlingen av 
extracellulärt ATP till adenosin och balanserar de extracellulära nivåerna av dessa molekyler, 
en viktig funktion då extracellulärt ATP frisätts i samband med vävnadsskada och aktiverar ett 
påföljande pro-inflammatoriskt värdsvar. Adenosin är även en av effektormolekylerna Treg 
använder för att hämma andra immunceller. MAIT celler, å andra sidan, är en okonventionell 
typ av T-celler, och tros ha en slemhinneskyddande effekt mot invaderande mikrober. I syfte att 
klargöra funktionen hos de här två celltyperna i kolontumörer, och deras inflytande på 
tumörtillväxten, har vi med hjälp av flödescytometrisk teknik, kartlagt och jämfört egenskaper 
och funktion hos tumörinfiltrerande CD39+ Treg och MAIT celler, med motsvarande celler 
isolerade från normal kolonvävnad och blod hos koloncancer patienter. Vi visar att både CD39+ 
Treg och MAIT celler ansamlas i kolontumörer jämfört med övriga studerade lokaler. I 
funktionella experiment har CD39+ Treg en uttalat hämmande effekt på tillväxten av 
konventionella T celler och ett högre uttryck av immunhämmande proteiner ses hos CD39+ Treg 
jämfört med Treg som saknar CD39-uttryck. Detta talar för att CD39+ Treg i kolontumörer är 
en särskilt immunhämmande Treg population med stor potential att hämma ett för patienten 
annars skyddande immunsvar mot cancern. En hög frekvens av CD39-uttryckande Treg bland 
totala antalet tumörinfiltrerande Treg, förefaller även vid en preliminär överlevnadsanalys att 
vara kopplat till en sämre överlevnad hos koloncancer patienter. Specifik eradikering av CD39-
uttryckande Treg i kolontumörer, i syfte att släppa på T-cells ”bromsen”, kan vara ett framtida 
alternativ till T-cells aktiverande antikroppar som än så länge fungerat sämre vid koloncancer. 
MAIT cellers funktion i kolontumörer är mindre studerat jämfört med funktionen hos 
tumörinfiltrerande Treg. Våra resultat visar nedsatt produktion av IFN-g hos tumörinfiltrerande 
MAIT celler men hur detta förhåller sig till ett eventuellt prognostiskt inflytande av MAIT celler 
på patienters prognos vid koloncancer är för tidigt att uttala sig om. Till skillnad från andra 
studier som kopplar samman MAIT celler med en försämrad patientprognos, visar våra 
preliminära överlevnadsdata att en hög grad av MAIT-cells infiltration i kolontumörer är kopplat 
till en bättre patientprognos. 
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1 INTRODUCTION 
1.1 Brief introduction to cancer 
Cancer is the malignant transformation of healthy human cells leading to 
disruption of tissue homeostasis and uncontrolled and invasive cancer growth 1. In 
this process, control mechanisms counteracting cancer transformation and cancer 
growth are impaired or circumvented, such as for example regulation of cell 
proliferation and cell death, and cancer immunosurveillance 2,3. Once a cancer has 
been established it is generally firmly rooted and if not treated by therapeutic 
intervention patients most often succumb due to the cancer. The risk factors to 
developing cancer are multiple, e.g. genetic predisposition, age, diet, and smoking 
4, but importantly, also chronic inflammation may promote cancer development of 
certain cancer types 4,5. 
As originally established by Hanahan et al., the different traits of an established 
cancer are referred to as the hallmarks of cancer 6. These hallmarks have since 
been revised 2, but the fundamentals of the original hallmarks largely remain the 
same. Six original hallmarks comprise, sustaining proliferative signaling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis, and the two newly defined 
hallmarks, are reprogramming energy metabolism and evading immune 
destruction 2. In addition, the importance of the tumor microenvironment and the 
interplay between cancer cells and other neighboring cells, e.g. stromal cells and 
immune cells, has recently been established in many types of cancer 2,7.  
While great progress has been made in cancer research leading to improved 
treatment strategies for many types of cancer, interventions to these hallmarks are, 
to a large extent, still missing.  
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1.2 Colon cancer 
The disease of interest in this thesis is colon adenocarcinoma, a subset of colon 
cancer that constitutes the major part of all colon cancer. However, due to its close 
resemblance with rectal cancer, these diseases are often looked upon as one entity 
in studies of molecular biology, which is colorectal cancer (CRC). Of CRC, 90% 
are adenocarcinomas originating from epithelial cells in crypt foci of the colorectal 
mucosa 8. In turn, mucinous adenocarcinoma and signet-ring cell carcinoma, 
constitute the majority of the remaining CRCs 9. In several instances, studies in the 
field have been conducted in a mixed cohort of colon and rectal tumors, but 
important distinctions between colon and rectal cancer are present 9-11.  
1.2.1 Incidence and mortality 
The incidence of CRC is ranking as the third highest in the world with over 1.8 
million estimated cases in 2018, and out of these cases approximately 61% are 
colon cancers 12. Incidence is higher in Western or transitioned countries, about 3-
fold higher compared to transitioning countries, but as transitioning countries take 
on a more westernized lifestyle the global incidence rates of CRC are expected to 
increase 12.  
CRC is inarguably a major malefactor to human health, ranking as the second 
highest contributor to all cancer mortality worldwide 12. Currently, the combined 
mortality rate of colon and rectal cancer is the most accurate, since, at least in the 
United States, the mortality cases of rectal cancer are still often classified as colon 
cancer 13.  
1.2.2 Etiology and risk factors 
The largest part of colorectal tumors, arise spontaneously, but at least 5% of all 
CRC cases have identifiable genetic predisposition associated with hereditary 
cancer syndromes, including for example Lynch syndrome and familial 
adenomatous polyposis (FAP) 14,15. To have a first degree relative with CRC highly 
increases the risk of developing cancer and the risk is further enhanced with a 
combined heredity of first, second and third degree relatives with CRC 16. Lynch 
syndrome, previously classified into the group of “nonpolyposis hereditary 
cancer” (HNPCC) 17, is the most common of the hereditary cancer syndromes 18. 
It is associated with mutations of DNA repair mechanisms, a common trait also 
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for sporadic CRC and thus of high interest to current research in various clinical 
implications of CRC 17,19. Also FAP, the second most common group of 
syndromes associated to hereditary cancer 18, display similarities with sporadic 
CRC, and constitutive activation of the Wnt signaling pathway due to truncation 
of the adenomatous polyposis coli (APC) gene is present in both FAP and the 
majority of colorectal tumors 20. In more than 70% of human colon cancer cases, 
a mutation in the tumor suppressor APC gene is considered as the initiating event 
of the transformation into aberrant intestinal crypt foci and adenomas 21. The 
specifics of the genetic and molecular landscape driving carcinogenesis in CRC is 
further elaborated on in the next section.  
The risk factors of CRC are several and can for simplification be divided into 
unmodifiable and modifiable risk factors. Unmodifiable risk factors, i.e. risk 
factors which cannot be influenced by the patient, include age, male sex, genetic 
predisposition and inflammatory bowel disease, while modifiable risk factors, that 
can be influenced by the patient, include smoking, excessive alcohol consumption, 
high consumption of red and processed meat, obesity and diabetes 4. Genetic 
predisposition and inflammatory bowel disease are less frequent risk factors on a 
population basis but associated to a higher relative risk of developing CRC 16,22. 
1.2.3 Carcinogenesis and subtyping 
Carcinogenesis 
During the malignant transformation of healthy tissue cells, the cells gradually 
acquire somatic mutations as well as other types of genetic alterations, and after 
acquiring a critical amount of these genomic alterations the tumor will convert 
from a pre-malignant state into a fully malignant state with uncontrolled cancer 
growth 1 (Figure 1). In the colon, this process is best exemplified by the adenoma-
carcinoma sequence; the gradual dysplastic transformation of a pre-malignant 
adenoma into a malignant adenocarcinoma 23. Both hereditary cancer syndromes 
associated with CRC and sporadic CRC are believed to develop through these 
steps of transformation 18,24. The phenotype of genetically altered colorectal 
tumors is dependent on the translational effects of mutations in oncogenes and 
tumor suppressor genes, i.e. genes that harbors the potential to cause cancer and 
becomes either activated (oncogenes) or inactivated (tumor suppressor genes) 
upon genetic alteration 2. Oncogenes (e.g. KRAS, PIK3CA) and tumor suppressor 
genes (e.g. APC, TP53, SMAD4) in CRC, in turn affects intracellular signaling 
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pathways regulating for example cellular proliferation and survival 25,26. In a recent 
large exome-sequence analysis of 224 colorectal cancer samples by The Cancer 
Genome Atlas Network, twenty-four genes were significantly mutated in 
colorectal tumors 10, but a single colorectal tumor may harbor up to 70 genomic 
alterations per tumor affecting protein-coding genes 1. Of these altered genes, the 
majority are however passenger mutations and only a small fraction are actual 
“driver” mutations, i.e. mutations associated with a selective growth advantage to 
the tumor cell 1.  
 
Figure 1. CRC development. Wang et al. Sci Rep 2017;7:4281. Adapted. 
 
Genetic instability pathways 
At least three major pathways of genetic instability have been identified in CRC: 
the chromosomal instability (CIN), microsatellite instability (MSI), and CpG 
island methylator phenotype (CIMP) pathways.  
The CIN pathway is characterized by large chromosomal alterations leading to 
imbalances in chromosomal number and loss of heterozygosity (LOH), i.e. loss of 
one of the two alleles of a functional gene, e.g. a tumor suppressor gene, rendering 
the cell more sensitive to subsequent mutation of the remaining intact allele 27. 
Colorectal tumors arising through the CIN pathway constitute the majority of 
colorectal tumors, accounting for approximately 65-70% of all sporadic CRC cases 
and also the inherited syndrome FAP 27,28.  
The MSI pathway is characterized by tumors with hypermutation and ubiquitous 
somatic mutations at repetitive sequences (microsatellites) of specific DNA 
markers, and accounts for about 15% of all CRC cases, of which 3% are associated 
with Lynch syndrome 29. These MSI tumors have defective mismatch repair 
(MMR) systems and mutations in genes responsible for enzymatic DNA repair, 
e.g. the mammal gene homologues of the prokaryotic mutS and mutL; the Mut S 
homologue (MSH) and Mut L homologue (MLH), respectively 29,30.  
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The CIMP pathway, the last of the three major pathways of genetic instability, 
stands for DNA hypermethylation in CpG-rich promotors which results in 
silencing of affected genes 31. It is highly associated with mutation in the proto-
oncogene BRAF 32. However, overlap exists between these genetic pathways, e.g. 
70-80% of MSI tumors also display gene promoter hypermethylation and silencing 
of the MSL1 gene associated with the CIMP pathway 31.  
Consensus molecular subtypes 
Based on a high degree of heterogeneity among colorectal tumors on the gene 
expression level, an alternative classification system, the consensus molecular 
subtypes (CMSs) of CRC has been formed, including four CMSs with 
distinguishing features: CMS1 (microsatellite instability immune, 14%): 
hypermutated, microsatellite unstable, strong immune activation and enriched for 
BRAF mutations; CMS2 (canonical, 37%): epithelial, microsatellite stable with 
high CIN, marked WNT/MYC signaling activation, EGFR amplification or 
overexpression and mutant TP53; CMS3 (metabolic, 13%): epithelial, evident 
metabolic dysregulation, low CIN, moderate WNT/MYC pathway activation, 
mutant KRAS and phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit 
alpha gene (PIK3CA), and insulin-like growth factor binding protein 2 (IGFBP2) 
overexpression; and CMS4 (mesenchymal, 23%): CIN/MSI heterogeneous, 
prominent transforming growth factor beta (TGF-b) activation, neurogenic locus 
notch homolog protein 3 (NOTCH3)/vascular endothelial growth factor receptor 
2 (VEGFR2) overexpression, stromal invasion and angiogenesis” 9,33,34. Even 
though the CMSs classification system of CRC cannot stratify all colorectal tumors 
into CMSs (13% of samples display mixed features), it is nowadays considered as 
the most robust stratification system of colorectal tumors with regard to biological 
interpretability 33. To date, several in vitro and in vivo models of these CMSs have 
been developed to account for this tumor heterogeneity and allow for improved 
translation between experimental and clinical studies concerning for example drug 
development 35-37. Interestingly in this context, further differentiation between 
colon and rectal cancer may also unravel from the CMSs classification system. 
Colon and rectal cancers have recently been shown to have highly similar patterns 
in terms of genomic alteration, excluding the hypermutated tumors which are 
rarely present in the rectum 9,10, while tumor clustering into CMSs has proven more 
difficult across anatomic boundaries 11. In addition to the mechanisms of 
carcinogenesis accounted for in this section, colon cancer may also undergo 
additional transformation at later time-points during disease, due to for example 
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immune escape mechanisms or treatment associated alterations 3,38. This will be 
discussed in the following chapters of the thesis. 
1.2.4 Diagnosis and clinical parameters 
The prevailing clinical diagnostical or histopathological classification of CRC is 
undoubtedly the TNM-classification, recently updated in the 8th edition of the 
TNM Classification guidelines of malignant tumors by the Union Internationale 
Contre le Cancer (UICC) 39. It contains tumor classification with regard to local 
invasion depth (T stage), lymph node spread (N stage) and distant metastases status 
(M stage); and these three stages are combined into an overall TNM-stage 4. The 
T stage of the tumor (Tis-T4b) refers to depth of tumor invasion into the 
surrounding tissue, and spans from in situ localization (Tis) to the serosa (T4a) or 
neighboring tissues/organs (T4b) 39. Importantly, tumor size is currently not 
incorporated into the TNM-stage 40. The N stage of the tumor (N0-N2b) spans 
from no lymph node involvement (N0) to cancer in 7 or more regional lymph 
nodes (N2b) 39. The M stage (M0-M1c) spans from no distant metastases to 
peritoneal metastases with or without organ involvement 39,41. Common sites of 
metastasis in CRC are to organs such as the liver, lungs, bone, brain, intra-
abdominal organs and the peritoneum 9,41. Finally, the combined TNM-stage (0-
IVB) spans from in situ carcinoma with no affected lymph nodes and no distant 
metastases to any T or N stages but with peritoneal metastases with or without 
organ involvement 39. 
In addition to the TNM-stage of colorectal tumors, tumor differentiation grade and 
tumor location are also important diagnostic factors in CRC as described below 
23,42. The grading system in CRC (grade 1-3) entails well-differentiated (grade 1), 
moderately differentiated (grade 2), and poorly differentiated (grade 3) tumors 33 
(Figure 2 and 3). In addition to the routine based grading of colorectal tumors 
during histopathological examination, also pre-malignant lesions are graded, but 
according to histological type, size and grade of dysplasia rather than grade of 
differentiation and stage as in CRC 43. Despite a more favorable prognosis for 
patients with MSI-H tumors compared to MSS tumors in CRC 44, as discussed in 
the following section, MSI-H tumors are generally more poorly differentiated and 
present with a greater depth of invasion compared to MSS tumors 30,45. 
Interestingly also, the likelihood of presenting with an MSI-H tumor is higher in 
colorectal tumors of low TNM-stage (stage I-II) 30. In addition to the TNM-stage 
and the tumor differentiation grade, tumor location is also an important diagnostic 
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factor in CRC. Conventionally, tumors proximal to the splenic flexure are defined 
as right sided and tumors distal to the flexure as left sided 42. This division has 
important clinical bearings and the potential advantages with a more precise 
classification according to tumor location is currently under evaluation 42,46.  
The majority of colorectal tumors are single primary tumors, but in rare cases and 
more frequently in patients with inflammatory bowel disease (IBD) and CRC 
associated to hereditary cancer syndromes, a patient initially presents with more 
than one primary tumor, referred to as synchronous CRC 47. Metachronous CRC, 
another important diagnostic subgroup of CRC, refers to a consecutive colorectal 
tumor occurring more than 6 months after the index tumor 47. For optimal 
classification according to the TNM-stage, pre-operative evaluation usually entails 
a custom selection of imaging techniques dependent on the clinical scenario, e.g. 
computed tomography (CT) colonography, magnetic resonance imaging (MRI), 
and positron emission tomography (PET)/CT colonography 48. Furthermore, 
colonoscopic examination to detect and remove pre-malignant lesions, such as 
serrated polyps and adenomas, is an important measure to reduce the risk of later 
CRC development, prone to occur in a minority of these patients 42,43.  
Colorectal tumors develop slowly, granting an opportunity for yet another 
diagnostic tool which is molecular biomarkers, involved in secondary prevention 
of CRC and early cancer detection 4. However, despite intense research, the 
currently available biomarkers, e.g. fecal hemoglobin, carcinoembryonic antigen 
(CEA), and CA19.9, in many instances cannot provide prognostic details for 
individual CRC patients 49. Analysis of the MSS/MSI status of colorectal tumors 
is recommended, but has not yet been fully introduced in clinical practice 30. For 
both CRC and pre-malignant lesions associated with CRC, several studies are 
currently evaluating a wide spectrum of potential biomarkers, ranging from 
microRNAs (miRNAs) 26,50 to biomarkers associated with the consensus 
molecular subtypes of CRC 34,43,51. 
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Figure 2. Colorectal adenocarcinoma, moderately differentiated, Stage I.  
Human Protein Atlas. www.proteinatlas.org 
 
Figure 3. Normal colon. Human Protein Atlas. www.proteinatlas.org 
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1.2.5 Treatment and prognosis 
Treatment 
The predominant therapeutic method of choice in CRC patients is surgical removal 
of the tumor 4. Surgery is performed in virtually all patients apart from those with 
severe un-operable metastatic disease. In addition to surgery, the other forms of 
therapeutics in CRC are radiotherapy, chemotherapy and targeted molecular 
therapy 52,53. For both colon and rectal cancer, the specific treatment protocol for 
each cancer is largely dependent on the TNM-stage classification. The common 
chemotherapeutic agent of choice in colon cancer is 5-flurouracil (5-FU), which is 
routinely used as adjuvant chemotherapy in stage III colon cancer and some stage 
II colon cancers of high risk of cancer relapse (T4 tumors) 4,9. The standard 
treatment protocol of colon and rectal cancer have some distinctive differences. 
The surgical procedure to treat colon cancer lack international standardization with 
regard to the tumor resection margin during a standard partial colectomy 54, while 
the surgical procedure to treat rectal cancer is highly established world-wide, i.e. 
with proctectomy or proctocolectomy and a total mesorectal excision (TME) 9. 
Also, neoadjuvant chemotherapy, i.e. chemotherapy given before the main 
treatment, is the standard treatment for stage II and III rectal cancers, but 
commonly not used in colon cancer 55. Targeted therapy in CRC, e.g. molecular 
targeting to inhibit the activities of vascular endothelial growth factor (VEGF) and 
epidermal growth factors (EGFRs), is mostly used in advance metastatic disease 
56. In addition, specific immunotherapeutic targeting is highly related to the scope 
of this thesis and cancer immunotherapy will be discussed in a later chapter.  
Prognostic markers 
Several combined factors determine patient prognosis in CRC, and apart from 
determining tumor stage, it is also important to account for tumor heterogeneity 
by determining the specific genetic and molecular subtype of each individual 
tumor. In this context, it has been shown in several studies of stage II and III colon 
cancer, that MSI-H tumors, also classified as CMS1, have a more favorable 
prognosis compared to MSS tumors, i.e. tumors typically classified as CMS2 and 
CMS3 34,57. However, despite improved survival of CRC patients with MSI-H 
tumors compared to MSS tumors, and a reduced overall risk of metastasizing 58, 
MSI-H tumors may also progress to metastatic adenocarcinoma 59. In addition, 
MSI-H colorectal cancers are differently enriched between tumor stages (20% of 
all colorectal tumors in stage II) but more rarely diagnosed at later stages of disease 
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(3-5% of all colorectal tumors in stage IV) 58,60. It is thus essential that patient 
groups are carefully stratified in survival studies. Of note, one study of 2720 stage 
III colon cancer samples, found a similar prognosis of MSI-H cancers (CMS1) and 
MSS cancers without KRAS or BRAF mutation (CMS2), while those MSS cancers 
harboring mutant KRAS or BRAF (CMS3) had a comparatively shorter 5-year 
survival 61. Prognostic impact of mutant BRAF in MSI-H cancers, present in 
approximately 50% of these patients, has so far been contradictory 62,63. 
Furthermore, colorectal tumors characterized by activation of signaling pathways 
related to epithelial-mesenchymal transition (EMT), constitute the subtype CMS4 
cancers and have a less favorable prognosis compared to CMS2 cancers 33,64. In a 
recent study, the prognostic biomarker PBX3, expressed in tumor cells, was 
required for EMT transition and may be useful to identify potentially aggressive 
stage II colon cancers and late progression in CRC 65. In addition, other prognostic 
biomarkers that serve to detect miRNAs and posttranslational modifications in 
colorectal tumors, such as glycosylation and ubiquitylation, are currently also 
under evaluation 66-68.  
Apart from the tumor stage and the specific genetic and molecular subtype of each 
colorectal tumor, as accounted for above, also other tumor characteristics play an 
important role in determining patient prognosis, in addition to the impact of the 
immune system and the purinergic signaling system on patient prognosis which 
will be covered in later parts of the introduction. Even though 75-90% of the MSI-
H cancers are located in the proximal or right sided colon, depending on how the 
tumors were classified 9,69, left sided colon cancer has a favorable prognosis 
compared to right sided in advanced stages of disease 70. Importantly, right and 
left sided tumors have a different embryonical origin which may explain these 
prognostic differences 42. As a consequence, a designated study to compare right 
and left sided tumors, carefully needs to consider group stratification, as reflected 
in a recent adjuvant chemotherapy trial where patient with stage II colon cancers, 
enriched for MSI-H tumors, but not stage III colon cancers, relapsed less 
frequently in patients with proximal cancers 71. Interestingly, among MSI-H 
cancers only, patients with proximal colon tumors had a more favorable prognosis 
compared to patients with distal colon tumors 69. Additional traits affecting patient 
prognosis in CRC are tumor size and type of distant metastasis. Tumor size 
correlates negatively with patient survival and advanced disease with peritoneal 
metastases correlates with a shorter overall survival compared to CRC patients 
with other sites of metastases 40,72.  
Filip Ahlmanner 
 11 
Predictive markers 
Predictive biomarkers in CRC, commonly referred to as biomarkers of treatment 
response, is outside the scope of this thesis, apart from predictive biomarkers of 
cancer immunotherapy which will be discussed in a later chapter of the thesis. 
However, a brief summary of the topic is motivated before closing this 
introductory section on colorectal cancer. An important feature of MSI-H colon 
cancers is poor response to 5-FU-based adjuvant chemotherapy, as shown when 
comparing patients with MSI-H tumors receiving adjuvant chemotherapy 
compared to surgery alone 73. Furthermore, the heterogeneity of colorectal tumors 
with regard to tumor location and activated pathways, also advocates a correlation 
between different molecular subtypes and treatment response of targeted therapies. 
In this context, the first acknowledged treatment biomarker of metastatic CRC is 
poor response to EGFR-targeted therapy in tumors with KRAS exon 2 mutation 
(CMS3) 74. Also, colon cancers with mutated BRAF, commonly present in MSI-H 
and right-sided tumors (CMS1), have a poor treatment response to anti-EGFR 
therapy 70,75. In contrast, colorectal tumors wild-type for KRAS, NRAS, BRAF, and 
PIK3CA (quadruple-negative tumors) have been shown to respond better to anti-
EGFR therapy 38,76. Predictive biomarkers are currently also under evaluation with 
regard to inhibitors of the VEGF:VEGFR2 pathway associated to angiogenesis in 
advanced CRC disease 77. In addition, also in CRC patients with advanced disease, 
a polymorphism in the Vitamin D Transporter gene has been shown to affect 
treatment response of both anti-EGFR and anti-VEGF therapy 78. 
Regulatory T cells and mucosal-associated invariant T cells in colon adenocarcinomas; 
Phenotype and function 
 12 
1.3 Overview of the immune system 
After this introductory part on colon and colorectal cancer, we now switch focus 
to the immune system. The immune system composes a major organ system and 
serves to detect and fight off a broad variety of foreign insults to the human body. 
As such, it is highly engaged in combating infections and wound-healing, but also 
in internal organ stress of various origin and in cancer growth. In addition, a 
dysregulated immune system may result in chronic inflammation, autoimmune 
diseases, or allergy. The major organs of the immune system include primary 
lymphoid organs, i.e. the bone marrow and the thymus, and secondary lymphoid 
organs, i.e. lymph nodes, spleen, tonsils, Peyer’s patches and mucosa associated 
lymphoid tissue (MALT). Highly simplified, immune cells are formed in primary 
lymphoid organs and activated in secondary lymphoid organs. Prior to introducing 
cancer immunology, the core research field of the thesis, this section provides a 
basic overview of the composition and function of the healthy immune system.  
1.3.1 The innate versus adaptive immune system 
The response of the immune system to an invading pathogen, or an encounter 
perceived as foreign to the body, consists of principally two distinct responses. A 
direct response, referred to as the innate immune response, and an acquired or late 
response, referred to as the adaptive immune response 79. Distinct immune cell 
subsets are involved in the innate versus the adaptive immune response, but they 
are highly interconnected via dendritic cells (DCs), a major subpopulation of 
antigen presenting cells (APCs) 80.  
When a foreign invader, for example a pathogen, manages to breach the epithelial 
protective barrier of a random organ, it will be directly exposed to innate immune 
cells 81. The innate immune cells are phagocytic cells such as tissue resident 
macrophages, neutrophils and DCs, but also other types of immune cells such as 
natural killer (NK) cells, mast cells, eosinophils and basophils. In order to sense 
foreign encounter, phagocytic cells express surface-bound and intracellular 
pattern-recognition receptors (PRRs) that recognize pathogen-associated 
molecular patterns (PAMPs) 82. Also epithelial cells express some PRRs and play 
a significant role in innate immunity by producing proinflammatory cytokines 81. 
PRRs are basically categorized into three major subtypes, which are surface-bound 
and intracellular Toll-like receptors (TLRs), intracellular NOD-like receptors 
(NLRs), and retinoic acid-inducible gene 1 (RIG-1)-like receptors (RLRs) which 
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are cytosolic helicases 82. Upon stimulation of these receptors, a signaling cascade 
is initiated, often activating mitogen-activated protein kinases (MAPK) and the 
master transcription factor NF-kB, which results in the secretion of 
proinflammatory cytokines by innate immune cells, such as TNF-a, IFN-g and IL-
1, but also activation of various other effector cell functions 82-84. Furthermore, 
most immune cells express TNF-a receptors, and TNF-a itself can activate NF-
kB 85. Importantly, PRRs also respond to danger-associated molecular patterns 
(DAMPs) which are endogenous products of stressed or necrotic cells, and 
DAMPs thus serve as alarm signals to the body in case of foreign encounter or 
different types of diseases 86. An excess of DAMPs leads to a pro-inflammatory 
state in the tissue, due to activation of MAPK and NF-kB, and also activation of 
the inflammasome, i.e. a cytosolic multimeric signaling complex involved in 
immune responses towards foreign or host derived danger signals 86,87. In addition, 
changes in tissue homeostastis upon pathogen exposure or other types of diseases, 
also affect complement signaling and the release of acute-phase proteins such as 
for example C-reactive protein (CRP), both highly involved in the first phase of 
the immune response and a link to adaptive immunity 88,89. Yet another important 
signaling system in the first response is the interleukin-1 (IL-1) family of cytokines 
and receptors, and these receptors share similar functions with TLRs, both using 
the intracellular adaptor MyD88 for signaling via IL-1R-associated kinase (IRAK) 
family kinases to activate MAPK and NF-kB 90,91. 
While innate immune cells respond upon first recognition of a foreign invader and 
detect targets that are commonly shared between different types of invaders, 
adaptive immune cells react to more specific targets and require days to develop. 
The adaptive immune cells consist of T and B lymphocytes, and these are largely 
dependent on DCs to become activated 79. From the large pool of preformed T and 
B cells, always present in the blood and lymphoid tissues of a healthy individual, 
only the cells with specific receptors recognizing towards the invader will clonally 
expand upon activation in the lymph node and migrate towards the site of invasion 
92,93. In this manner, the adaptive immune response can generate a strong and well-
directed response towards the invader, and the precise mechanisms of this response 
will be presented in the following sections. Notably, the adaptive immune response 
serves as an additional level of protection in those instances when the innate 
immune response does not suffice. In addition, adaptive immunity may also 
generate memory that is a long-term protection through the formation of long-
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lasting memory cells and antibodies during the first response which can easily be 
reactivated upon re-exposure to the same pathogen 94,95. 
1.3.2 Intestinal immunology and the microbiome 
Due to the topic of the thesis, this brief summary of the mucosal immune system 
will focus solely on the intestinal immune system, and not specifically address the 
immune system at other mucosal sites, such as the urogenital tract or the 
respiratory system. The large intestine, i.e. colon and rectum, forms the distal part 
of the intestine and is protected from the outside by two mucus layers, one inner 
and one outer mucus layer, and a mucosal surface consisting of a single layer of 
epithelial cells supported by intercellular tight junctions and an underlying lamina 
propria (LP) 96,97. In contrast to the small intestine, the colonic wall is flat and lacks 
protruding villi, but the main tissue layers of the colon are otherwise similar to the 
small intestine, with three distinct layers underlying the mucosal surface, i.e. the 
muscularis mucosae, the submucosa and a muscular layer 98. The colonic 
epithelium is a glandular epithelium made up of several types of intestinal 
epithelial cells (IECs), including absorptive enterocytes but also stem cells located 
in the colonic crypt, numerous mucin-producing goblet cells, neuroendocrine cells 
and intraepithelial lymphocytes (IELs) 96,98. Also the LP consists of several 
different cell types, and in addition to its supporting role to supply the epithelial 
cells with blood vessels and lymph drainage, it contains numerous immune cells 
of different types.  
Homeostatic immune control at the intestinal mucosal site entails a variety of 
functions, ranging from protective functions, such as fighting of intestinal 
pathogens, to tolerogenic functions, such as preserving unresponsiveness to food 
antigens and commensal bacteria 99. As previously described, innate immune cells 
contribute significantly in this process, and for example macrophages are highly 
important to intestinal immune homeostasis 100. Also cytokines play a critical role, 
and in particular interleukin-10 (IL-10) have important immunoregulatory 
properties for gut homeostasis 101. Furthermore, the innate and the adaptive arms 
of intestinal immunity, are linked together in a complex structure of organized 
lymphoid structures (Figure 4). These include sites of antigen-presentation and 
lymphocyte activation, which are mesenteric lymph nodes (MLNs) and gut-
associated lymphoid tissue (GALT) such as for example Peyer’s Patches (PPs) and 
isolated lymphoid follicles (ILFs), but also lymphocyte effector sites such as the 
lamina propria (LP) 98. M cells, a subset of intestinal epithelial cells (IECs) 
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commonly present in the follicle-associated epithelium in the small intestine 102, 
are highly specialized at taking up and transporting antigen to the underlying DCs 
present in GALT or PPs, and similar mechanisms are believed to occur in ILFs of 
the colon 98,103. After antigen-uptake, DCs migrate to the MLNs of the small 
intestine or colon were they prime T cells 104,105. A more detailed description of 
the specific mechanisms behind these processes will be provided in the following 
chapters of the introduction.  
 
Figure 4. Immune cells in the gastrointestinal tract. Meng J, Sindberg GM and Roy S. 
Front Microbiol 2015;6:643
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Also the gut microbiota is highly interlinked with mucosal immunity. The 
microbiota consists of numerous commensal or non-pathogenic bacteria which 
live in synergy with the host and the host is dependent on commensal bacteria for 
a wide range of different functions, e.g. food digestion, vitamin synthesis, and 
lymphocyte development and differentiation 98. A state of tolerance between the 
mucosal immune system and the gut microbiota is therefore essential, and 
commensal bacteria-specific CD4+ T cells are highly important to this process 106. 
Also important in this context are a subset of innate immune cells, innate lymphoid 
cells (ILCs), which provides important cross-talk with other immune cell subsets 
such as CD4+ T cells to confer protection against both pathogenic and non-
pathogenic bacteria residing in the GALT upon epithelial barrier breach 107. IgA 
secretion by mucosal B cells also has an important role for establishing a healthy 
microbiota 108. Epithelial barrier breach in the intestine may overturn tolerance to 
commensal bacteria and lead to microbiota dysbiosis, i.e. an altered composition 
of the microbiota, eventually leading to various degree of immune hyperactivation 
109. This in turn may have implications for disease development and an altered 
microbial composition has been observed in IBD and CRC patients 109. Indeed, 
epidemiological studies have revealed an increased risk of CRC development in 
patients with IBD, which may partly be caused by the dysbiosis 110. Furthermore, 
a recent study by Grivennikov et al., observed increased epithelial permeability of 
bacteria in colorectal tumors, together with increased expression of IL-23 and IL-
17 111. These findings were confirmed in a mouse model of colorectal 
tumorigenesis, indicating a potential involvement of microbially driven tumor 
growth mediated by IL-23 and a tumoral IL-17 response. 
1.3.3 Lymphocyte activation and antigen-specificity 
This subchapter is a brief summary on the processes behind lymphocyte activation 
and specificity, and includes the development of both B and T lymphocytes (B and 
T cells) and their subsequent activation in draining lymph nodes by DCs upon 
antigen-presentation. Both B and T cells originate from pluripotent haematopoietic 
stem cell progenitors in the bone marrow (BM) and after their initial development 
in the BM, T cell progenitors migrate to the thymus, while B cells remain in the 
BM for their continued development 112. During their continued development in 
the BM and thymus, and prior to their release into the circulation as mature naïve 
B and T cells, they undergo a sequential maturation and selection process, resulting 
in the generation of naïve B and T cell subsets with highly specific B and T cell 
antigen receptors, BCRs and TCRs, respectively 93,113. Importantly, lymphocytes 
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with a strong responsiveness to self-antigens, i.e. antigens originating from 
proteins normally present in the host itself, will undergo negative selection to 
prevent the development of autoreactive B and T cells 93,113.  
The subsequent activation of naïve B and T cells occur in the secondary lymphoid 
tissues. In contrast to B cells, T cells cannot bind to native antigens by themselves 
and are dependent on APCs for their activation. Lamina propria DCs sample 
antigens and present them to T cells in the draining lymph nodes as small peptides 
on Major Histocompatibility Complex (MHC) class I or II molecules. Depending 
on the type of antigen, antigens are processed and loaded onto MHC class I and II 
molecules via different loading routes, i.e. in the endoplasmic reticulum for MHC 
class I peptides and in endosomes for MHC class II peptides 80. Apart from these 
normal routes of peptide loading, an additional MHC class I route exists for cross-
presentation of peptide antigens originating from other phagocytosed cells, such 
as tumor cells and virus-infected cells 114-116.  
In addition to its role in antigen-presentation, MHC class I expressed on the cell 
surface also inhibits targeting by cytotoxic NK cells 117. While MHC class I 
molecules are present on all human cells, MHC class II molecules are only present 
on professional APCs, such as DCs, macrophages, and B cells. The classical DCs 
(cDCs) in the intestine express the integrine CD103 and cDCs are required for 
tolerogenic as well as protective immune responses 116,118. Importantly, only those 
naïve T cells with a peptide-MHC specific receptor are activated by the DCs and 
form large clones of T cells towards the antigen with TCRs of identical specificity. 
In addition to TCR-signaling upon cognate antigen encounter (signal 1), naïve T 
cells also require co-stimulation by APCs (signal 2), and cytokines from APCs and 
other neighboring cells (signal 3) to become activated 119,120. More specifically, 
APCs provide co-stimulation by CD80 and CD86 which bind to CD28 on naïve T 
cells. Cytokine signaling (signal 3) during activation will be addressed in a later 
section in the introduction.  
In contrast to T cells, naïve B cells are able to take up antigen themselves in the 
draining lymph nodes via their BCRs, process it, and later present it to antigen-
specific T helper (Th) cells to gain specific help from T cells 93,121. This pathway 
of B cell activation thus represents the T cell dependent pathway of B cell 
activation, but in some instances B cells can also be directly activated by some 
types of antigen independently of T cells, commonly in response to large 
polysaccharide structures 93. B cells that receive T cell help usually migrate into 
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germinal centers (GC) of PLNs or MALT, where they further differentiate and 
become highly specific antibody-secreting B cells 108,121. 
1.3.4 Immune cell migration 
Immune cell migration is similar between all subsets and involves three major 
steps, i.e. rolling, adhesion and transmigration. Whilst innate immune cells such 
as neutrophils are able to respond and migrate directly towards inflammatory 
signals in the tissue, initiated by epithelial cells and tissue-resident macrophages 
and mediated by endothelial cells, lymphocytes first need to undergo antigen-
induced activation and priming in peripheral lymphoid organs 122. Hence, naïve B 
and T cells circulate between blood and PLNs and mucosal associated lymphoid 
tissue (MALT) in search for cognate antigen. Already upon their original release 
into the circulation, both naïve B and T cells destined for mucosal tissues, express 
a key integrine a4b7 which allows them to bind to endothelial cells of high 
entothelial venules (HEV), a specific endothelium present in peripheral lymphoid 
organs 123. More specifically, a4b7 on naïve lymphocytes binds to mucosal 
addressin cell adhesion molecule 1 (MADCAM-1) and peripheral lymph node 
addressin (PNAd), expressed on HEVs 124,125. Whilst the interaction between a4b7 
and MADCAM-1 is essential for both lymphocyte rolling and adhesion to the 
endothelium, also additional interactions between selectins and oligosaccharide 
ligands promote this process 123. Upon firm adhesion to the HEVs, the 
lymphocytes are able to transmigrate into PLNs and MALT where they encounter 
migratory DCs, e.g. CD103+ DCs, as well as free antigen, both recently arrived via 
the draining lymphatic vessels 99,123.  
Importantly, during B and T cell activation also specific homing properties will be 
acquired by lymphocytes, and for example vitamin A is metabolized into retinoic 
acid by DCs in the intestinal LP and confers gut homing-properties to both B and 
T cells 124,126. These homing properties consists of enhanced surface expression of 
the gut-homing adhesion molecule a4b7 but also upregulation of various 
chemokine receptors on the lymphocyte cell surface, e.g. CCR9 and CCR10 124,126, 
and license activated lymphocytes to migrate from the site of activation to their 
final destination in the intestinal tissue. Typically, lymphocytes express a 
combination of several different chemokine receptors and migrate towards a 
gradient of chemoattractants in the affected intestinal tissue, such as specific 
chemokines 127. Depending on differences in the concentration of their chemokine 
receptor targets along the length of the intestine, chemokine receptors confer 
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specific homing properties, e.g. CCR9+ and CCR10+ lymphocytes home 
preferentially to the small intestine and colon, respectively 125. This allows for 
specific recruitment of antigen-specific B and T cells to their final destinations. 
1.3.5 Effector lymphocytes 
Intestinal lymphocytes 
As previously described, antigen-specific B and T cells that encounter their 
cognate antigen in secondary lymphoid organs of the intestine, i.e. GALT and 
MLNs, will first undergo activation and clonal expansion and then migrate to their 
mucosal effector sites in the LP or the intestinal epithelium 93,119. As a 
consequence, the majority of lymphocytes present at these mucosal effector sites 
will be antigen-experienced effector cells 95,128. Also effector memory T cells are 
present here, and can be directly activated in the intestinal tissue upon re-encounter 
with their cognate antigens 129. However, the mucosal surface of the intestine is a 
shared site between adaptive and innate immune cells, and as such it composes a 
highly heterogenous environment with a broad range of different immune cells 
with both protective and tolerogenic functions. During immune homeostasis, 
specialized tissue-resident lymphocyte subsets include tissue-resident memory T 
(TRM) cells, ILCs, unconventional or “innate-like T cells” (e.g. natural killer T 
(NKT) cells, mucosal-associated invariant T (MAIT) cells, gd T cells, and 
CD8aa+ intraepithelial lymphocytes (IELs) 128,130,131. Importantly, some of these 
immune cell subsets are able to self-renew in the intestine and are not dependent 
on circulatory precursors for this process 130. MAIT cells will be further discussed 
at a later stage in the introduction.  
In the context of this thesis, also conventional T cells are of great importance and 
different T cell subsets are highly involved in a wide range of mucosal immune 
responses in the intestine, e.g. pathogen clearance, inflammation, autoimmunity, 
allergy and tumor immunity 132-135. T cells can be divided into three main types, 
i.e. CD4+ T helper (Th) cells, CD4+ regulatory T (Treg) cells and CD8+ cytotoxic 
T lymphocytes (CTLs). In turn, CD4+ Th cells can be further divided into subtypes, 
of which Th1, Th2 and Th17 cells are the most studied 128,133. During T cell 
activation in the MLN, naïve CD4+ T cells will be exposed to a distinct cytokine 
environment (signal 3) provided by DCs and neighboring cells, which will decide 
what subset the naïve CD4+ T cell will differentiate into 119. During this process, 
each Th cell subset will acquire specific effector functions governed by lineage-
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specific transcription factors and epigenetic gene modifications 133. Furthermore, 
due to changes in the cytokine milieu in the intestine, T cell subsets may also, in 
some instances, display plasticity and overdrive its previous lineage commitment 
to convert into the phenotype of another T cell subset 133,136. In contrast to CD4+ 
Th cells and CTLs, which provide protective immunity towards foreign insult, the 
major function of CD4+ Treg is to modulate immune responses and Treg are 
particularly important in immune homeostasis due to their ability to suppress the 
function of other T cell subsets 137. In this section, features and function of each of 
these T cell subsets will be presented. 
Th1 cells 
In order for naïve CD4+ T cells to differentiate into Th1 cells in secondary 
lymphoid organs they are dependent on a specific cytokine milieu (signal 3) 
consisting of primarily IL-12 and IFN-g, but also TNF-a 92,138. IL-12 and IFN-g, 
in large produced by neighboring DCs and NK cells, activate the transcription 
factors STAT1 (signal transducer and activator of transcription 1) and STAT4, 
respectively, which in turn activates T-box binding transcription factor (T-bet), the 
master transcription factor of Th1 cells 92,139. Whilst T-bet leads to the upregulation 
of a specific set of genes in the naïve CD4+ T cells and is required for Th1 cell 
differentation, it is however not a specific transcription factor for Th1 cells and is 
shared between several different immune cell subsets 139,140. TNF-a is also 
important for Th1 differentiation, but more with regard to co-stimulation (signal 
2) 92. Upon T-bet activation, Th1 cells acquire the ability to produce IFN-g and IL-
2, their main effector cytokines, and autocrine IFN-g signaling by Th1 cells thus 
also reinforces commitment to the Th1 lineage. In addition, T-bet itself also 
suppress the differentiation into other Th cell lineages by indirectly inhibiting other 
key transcription factors 92.  
Once fully developed, antigen-specific Th1 cells promote a type of cellular 
immunity, often referred to as type I immunity 141. Th1 effector cells are highly 
involved in protective immunity towards both infectious diseases and cancer 
135,138. Importantly, in the context of infectious disease, IFN-g secreted by Th1 cells 
enhances the phagocytic function of macrophages and promote CTL development 
142. However, in other settings, IFN-g may also promote autoimmunity and 
inflammation, due to its proinflammatory function 133.  
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Th2 cells 
Th2 cells stimulate type II immunity, often characterized by high IgE antibody 
titers and activation of various innate immune cells such as mast cells, basophils 
and eosinophils 141. Th2 effector cells are thus implicated in the immune response 
towards extracellular infectious agents and parasites, but also in allergy 134,138. The 
cytokines IL-4 and IL-2, drive Th2 differentiation by activating the transcription 
factors STAT6 and STAT5, respectively. STAT6 in turn upregulates GATA3 
(GATA-binding protein), the master transcription factor of Th2 cells 92. Upon 
GATA3 activation Th2 cells acquire the ability to produce the effector cytokines 
IL-4, IL-5, and IL-13 138. Furthermore, similar to T-bet which suppresses other key 
transcription factors, also GATA3 has been shown to downregulate STAT4 and 
suppress Th1 differentiation 92. 
Th17 cells 
Th17 cells, yet another important Th cell lineage which stimulate type III 
immunity, are characterized by activation of mononuclear phagocytes, neutrophil 
recruitment and epithelial antimicrobial responses 141. Th17 effector cells are 
involved in immune responses towards infectious diseases but are also implicated 
in autoimmune diseases 143. While type III immunity constitutes a highly pro-
inflammatory immune response, in large accounted for by secretion of IL-17A by 
the majority of Th17 cells 141, it has also been shown that Th17 cells in the intestine 
are a highly heterogeneous population and not always associated with type III 
immunity 144. Indeed, on rare occasions, IL-17A+ Th17 cells in the intestine have 
been shown to co-express either IFN-g or forkhead box P3 (Foxp3), the master 
transcription factor of Treg, and Th17 cells may still have unrecognized functions 
in intestinal immune homeostasis 144. Nevertheless, a clear pro-inflammatory Th17 
phenotype is evident in the majority of Th17 cells and increased numbers of IL-
17A+ Th17 cells have been observed in the intestinal mucosa of patients with IBD 
144. In addition to IL-17A, Th17 cells also frequently secrete IL-21 and IL-22,  and 
may also secrete IL-17F depending on environmental context 144. IL-22 provides 
antimicrobial defense and promotes epithelial cell homeostasis 141.  
The specific cytokine milieu that drives differentiation of naïve CD4+ T cells into 
conventional Th17 effector cells, as defined by IL-17A expression, consists of IL-
6, IL-21, IL-23 and a low concentration of TGF-b 92. These cytokines activate 
downstream STAT3 signaling which further activates the retinoic acid receptor-
related orphan receptor gamma-T (RORgt), the master transcription factor of Th17 
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cells 92. Interestingly, TGF-b also promotes the differentiation of naïve CD4+ T 
cells into peripheral Treg (pTreg) but only in a setting of high TGF-b 
concentration, and in the absence of IL-6 which otherwise counteracts Treg 
development. In this context, an overproduction of IL-6 will lead to a dysregulated 
Th17 response and autoimmunity 145. Also Treg, which frequently secrete TGF-b, 
may contribute to Th17 differentiation in the presence of IL-6 146. 
Treg 
As suggested by the name, regulatory T cells (Treg) are regulatory lymphocytes 
with a main function of maintaining immune homeostasis by regulating the activity 
of both self-reactive lymphocytes and other effector immune cells 147. As such, 
they are important in preventing autoimmunity and allergy, but also in executing 
anti-inflammatory responses to control and limit inflammation 133,147,148. In 
contrast to Th cells, Treg come in two flavors which are either thymus-derived 
Treg (tTreg) or peripheral Treg (pTreg) 92.  Of these, thymus-derived Treg are 
already lineage committed Foxp3-expressing T cells upon their release from the 
thymus 92. They are also more easily activated compared to peripheral Treg, i.e. 
via TCR engagement and IL-2 signaling alone, while peripheral Treg are activated 
in a similar fashion to the other Th cell subsets 149. In addition, thymus-derived 
Treg are preferentially self-reactive with TCRs of higher affinity towards self-
antigen compared to other naïve CD4+ T cells 147.  
pTreg are highly present at mucosal sites and TGF-b, IL-10 and IL-2 are key 
cytokines implicated in their induction 150-152. Of these, TGF-b signaling is critical 
for lineage commitment of pTreg, and activates the master transcription factor 
Foxp3 92,153. IL-10 and IL-2 signaling activate STAT3 and STAT5, respectively, 
which in turn enhances Foxp3 expression and Treg stability 92,152. Of note, both 
TGF-b and STAT3 are also involved in Th17 differentiation, but in a setting of IL-
6 signaling 145,152. Indeed, several factors determine pTreg lineage commitment, 
and commensal bacteria-derived molecules, granulocyte-macrophage colony-
stimulating factor (GM-CSF) and retinoic-acid, have all been associated with 
pTreg induction 107. pTreg in the intestinal mucosa may also be dependent on 
CTLA-4, as proven in CTLA-deficient mice which had an impaired accumulation 
of commensal bacteria-specific pTreg 154. Furthermore, Treg also display plasticity 
and may acquire traits of other Th cell subsets or altogether convert into another 
Th cell subset upon alterations of peripheral signaling cues 136,146,155-157. In 
addition, while Foxp3 is a key transcription for both nTreg and pTreg, it is not 
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specific to Treg and may also be expressed in human nonregulatory CD4+CD25- 
T cells upon stimulation in vitro 158. To date, the conventional markers used to 
identify Treg does not allow for differentiation between thymus-derived and 
periphal Treg 159.  
Several conventional cell markers are used in combination to identify Treg, and 
apart from the markers already mentioned (Foxp3, CD3 and CD4), additional basic 
Treg markers are CD25 (alpha chain of the IL-2 receptor) and CD127 (IL-7 
receptor) 160. Also the expression level of these markers is important and more 
specifically, Treg are identified as CD3+CD4+CD25hiCD127lowFoxp3+ cells. Other 
characteristic Treg markers are TGF-b, IL-10, CTLA-4, GITR, and neuropilin 
147,161,162, but these molecules are not specific to Treg. Importantly in this context, 
CD4+Foxp3+ T cells isolated from peripheral blood has been shown to be a 
heterogenous cell population when characterized by their combined expression of 
Foxp3, CD25 and CD45RA 163. Of the isolated cell fractions, two fractions were 
immunosuppressive putative thymic-derived Treg; 
CD4+CD45RA+CD25++Foxp3lo resting naïve Treg (Fr. I) and CD4+CD45RA-
CD25+++Foxp3hi activated or memory Treg (Fr. II), and one fraction was 
CD4+CD45RA-CD25++Foxp3lo non-suppressive putative effector T cells 163. This 
confirms previous in vitro findings, which suggests that Foxp3 expression in 
combination with a high expression of CD25 is also associated with the activation 
state of T cells and not only confined to Treg 158.  
In order for Treg to impose regulatory function on other immune cells, Treg are 
equipped with homing molecules and specific chemokine receptors, which direct 
them to the appropriate site in the tissue 164. Importantly, Treg exert regulatory 
function both in the tissue by suppressing proliferation and function of effector 
immune cells such as T cells, NK cells and NKT cells 165, and in peripheral 
lymphoid organs by regulating T cell activation and differentiation 164,165. Treg 
also interact with DCs and macrophages to induce tolerogenic properties in these 
cells 166. In addition, despite an ability of Treg to perform bystander suppression 
on neighboring immune cells in vitro, Treg are primarily designed to exert antigen-
specific immunosuppression and operate close at hand to effector T cells of the 
same antigen-specificity 151,167. The effector functions of Treg consist of a wide 
range of suppressive mechanisms, basically including two major modes of action, 
i.e. cell-cell contact independent and cell-cell contact dependent mechanisms. 
These mechanisms can also be classified into different functional modes of 
suppression (Figure 5), which are production of anti-inflammatory cytokines 
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(TGF-b, IL-10 and IL-35) 166,168-170, cell-cell contact dependent T cell inhibition 
(CTLA-4, PD-1 and PD-L1) 161,171,172, cytolytic killing of target cells (perforin and 
granzyme B) 161, modulation of antigen presenting cell maturation and function 
(CTLA-4) 161,173, and disruption of metabolic pathways (IL-2 deprivation and 
generation of immunosuppressive adenosine) 161,174.  
 
Figure 5. Effector functions by Treg. 
While the specifics of some of these mechanisms will be explained more in detail 
in the coming sections, i.e. cytolytic killing of target cells and generation of 
immunosuppressive adenosine by Treg, others will be briefly overviewed in this 
section. CTLA-4 and PD-1 are commonly expressed by Treg but instead of 
propagating an inhibitory signal to Treg upon binding to its respective ligands, as 
is the case for other effector T cells upon binding of these co-inhibitory surface 
molecules, CTLA-4 and PD-1 signaling by Treg propagate an inhibitory signal in 
the opposite direction, acting on DCs and effector T cells, respectively 161,171,173. 
Treg can also suppress effector T cells via PD-L1 by binding to PD-1 on effector 
T cells in a more conventional manner 171,172.  
CD8+ T cells  
CD8+ T cells or CTLs are already lineage committed naïve T cells upon their 
release from the thymus and undergo a faster differentiation upon antigen-specific 
encounter in the peripheral tissue compared to Th cells 175. Upon clonal expansion 
and differentiation, effector CD8+ T cells migrate to the appropriate site, where 
they similar to Th1 cells, mediate type I immunity as previously described 141. 
Accordingly, CD8+ T cells and Th1 cells often work in synergy to provide an 
effective and long-lasting response against typically intracellular microbes but also 
cancer 132,135,176,177. Like Th1 cells, conventional CD8+ T cells also express T-bet 
and IFN-g, and T-bet is induced in CD8+ T cells by pro-inflammatory cytokines 
such as IL-12 141,178. In addition, conventional CD8+ T cells are specialized at 
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mediating cytotoxicity and thereby kill target cells in a cell-cell contact dependent 
manner inducing apoptosis in target cells 132. Upon release by CTLs of cytolytic 
granules containing perforin and granzyme A and B, perforin causes a pore-
formation in the target cell membrane enabling passage of caspase-activating 
granzymes into the cytosol 179,180. The death receptor pathway, which involves 
interactions between the cell surface death receptor Fas on target cells and Fas 
ligand (FasL) on CTLs, is an additional cytolytic pathway by CTLs also leading 
to caspase dependent apoptosis in the target cell 181.  
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1.4 Specific properties of CD39+ Treg and MAIT cells 
CD39+ Treg 
CD39, also called ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1), 
is an ectoenzyme expressed on the surface of various immune cells but also on 
several other cells such as mesenchymal stem cells (MSCs) and endothelial cells 
182,183. It is an important regulator of purinergic signaling, and responsible for the 
first and rate-limiting step in the conversion of extracellular ATP (eATP) into 
adenosine. Upon hydrolysis of eATP into ADP and AMP by CD39, another 
ectoenzyme, CD73 in turn hydrolyzes AMP into adenosine 182,184. Levels of 
extracellular ATP and adenosine are tightly regulated, but in response to increased 
levels of eATP, which commonly follows upon tissue damage, an increased 
activity by CD39 and CD73 is required to shift the balance from a highly 
proinflammatory state to a new equilibrium. In high concentrations, eATP thus 
serves as a danger signal to stimulate the immune system to an appropriate 
response 185,186. However, also during normal conditions ATP is constantly present 
in the extracellular space. This is also true for adenosine, and purinergic signaling, 
via adenosine and ATP-receptors, is part of an important signaling system highly 
involved in the regulation of various immune cell functions, e.g. migration, 
activation, differentiation and suppression 185,187. The adenosine receptors are a 
family of G protein-coupled receptors (GPCRs), and includes the A1, A2A, A2B, 
and A3 receptors 188. For example, adenosine signaling via the A2BR receptor 
induces tolerogenic properties in APCs by alternative activation (Figure 6) 182. 
ATP-receptors, on the other hand, can be either GPCRs (P2Y receptors) or ligand-
gated ion channels (P2X receptors) 189.  
Treg frequently express CD39 on their surface, and commonly CD39 expression 
is enriched among Treg both in various tissues of healthy individuals and different 
settings of disease 182,190-192. On the other side of the spectra, CD39 expression by 
Treg can also be reduced, as has been shown in peripheral blood of multiple 
sclerosis (MS) patients 186,193,194. In mice, CD39 is expressed by a fraction of 
thymic-derived Treg already upon their release from the thymus 190, but an 
upregulation of CD39 during disease in different T cell subsets, which lack CD39 
expression under normal conditions, also suggests that CD39 can be upregulated 
in the tissue in response to different stimuli 195,196. Also in mice, CD39 expression 
was shown to be driven by upregulated Foxp3 expression and enhanced by TCR-
ligation 186, and interestingly in this context a recent study in humans provide 
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evidence of a stronger stability and function in CD39+ Treg compared to CD39- 
Treg during inflammatory conditions 197. CD39+ Treg are also enriched in 
colorectal tumors 198-200, but their specific function in this setting remains to be 
elucidated. However, a high immunosuppressive potential of CD39+ Treg have 
been shown both in healthy individuals and several diseases 191,196,201,202. In this 
context, CD39+ Treg are believed to exert immunosuppressive function via 
adenosine (Figure 6) but also via other more conventional Treg effector functions, 
such as secretion of TGF-b and IL-10 172,174,196,199. Also tumor stroma and tumor 
cells can express CD39, and in a recent study a CD39-inhibitor alleviated 
immunosuppression by CD39+CD73+ cancer cells and restored proliferation of 
both CD4+ and CD8+ T cells 203. In addition, purinergic signaling also has direct 
effects on tumor growth in colon cancer, but a defined role of adenosine and ATP-
signaling in this context remains to be elucidated 204-207.  
 
Figure 6. Generation and signaling effects of adenosine.  
Ohta et al. Front Immunol 2014;5:304. 
MAIT cells 
Mucosal-associated invariant T (MAIT) cells are innate-like T cells, and in healthy 
individuals MAIT cells are predominantly located in peripheral blood, the 
intestine, and in the liver 208-211. At these sites, and especially in the intestine, they 
are suggested to provide a first line defense against microbial pathogens 212,213. 
However, MAIT cells have also been implicated both in autoimmune diseases 
214,215 and inflammatory bowel disease 216,217. MAIT cells express a semi-invariant 
TCR consisting of one invariant a chain (Va7.2 joined to Ja33), combined with a 
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limited number of Vb chains 208,218,219. Apart from Va7.2, also IL-18R and the NK 
receptor CD161 are commonly used to identify MAIT cells 209,219. The MAIT cell 
TCR recognizes microbially derived vitamin B (riboflavin) metabolites bound to 
the invariant and highly conserved HLA-Ib major histocompatibility complex-
related protein 1 (MR1) 220,221, which is expressed on both APCs and epithelial 
cells 208,222. Activation of MAIT cells occur primarily in the peripheral tissue and 
importantly, to become activated, MAIT cells do not need to pass the PLNs prior 
to entering the tissue 223. Once in the tissue, MAIT cells are readily activated by 
cognate antigen, but can also respond to antigen-independent stimuli, such as 
microbially induced cytokines 212,224. Effector functions of MAIT cells are partly 
context dependent but generally comprise cytotoxic ability and secretion of both 
Th1 and Th17 type cytokines 221,225-228.   
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1.5 Cancer immunology 
The link between cancer and the immune system is complex and needs to be 
assessed from different perspectives. On the one hand, inflammation itself may 
promote cancer, as clearly demonstrated by a higher risk of cancer development in 
several types of inflammatory diseases 110,229,230, and on the other hand the immune 
system responds to the cancer by initiating an anti-tumor immune response in order 
to eliminate the cancer 231. In addition, cancers may also induce an inflammatory 
or tolerogenic microenvironment that promotes further cancer growth 110,232,233. 
The process by which the immune system responds to and shapes the cancer is 
referred to as cancer immunoediting and involves three phases, i.e. elimination, 
equilibrium, and escape 231. Interestingly, this interaction goes both ways, and if a 
cancer clone reaches the later phases of cancer immunoediting it has transformed 
and will no longer be detected by the immune system. The cancer will continue to 
grow in an uncontrolled manner and is out of reach from the immune system. 
Cancer immunosurveillance is a related process to cancer immunoediting, but 
refers mostly to the elimination phase and involves cooperate forces of innate and 
adaptive immunity to eradicate the cancer 234-236.  
Classification of the immune contexture in human tumors, which include the 
immune cell compartment, microenvironment of the tumor, and the profile of 
expressed cytokines and chemokines, is a recent approach to determine the pro- 
and anti-tumorigenic properties of the immune infiltrate present in the tumors 237. 
These studies have led to the introduction of the “immunoscore”, a scoring system 
to assess the importance of the intratumoral immune landscape in human cancers 
238,239, and the immunoscore was recently validated in patients with colon cancer 
and provides clues with regard to the risk of disease recurrence 240. In another 
study, it was shown that immunoscore in CRC is a stronger predictor of patient 
survival than microsatellite instability 29,241. Despite the obvious importance of 
tumor-infiltrating immune cells in CRC, only MSI-H colorectal tumors, a minority 
of all CRC, have so far responded to treatment with immune checkpoint inhibitors 
242,243.
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2 AIMS 
Both CD39+ Treg and MAIT cells accumulate in colon adenocarcinomas but their 
independent contribution to patient outcome remains unclear. The overall aim of 
this thesis was to investigate the specific functions of these immune cells in order 
to determine their potential as therapeutic targets in colon cancer.  
Specific aims were as follows:  
1. Determine the phenotype and function of intratumoral CD39+ 
and CD39- Treg in colon adenocarcinomas ex vivo.  
 
2. Investigate the suppressive ability of intratumoral CD39+ and 
CD39- Treg in colon adenocarcinomas in vitro. 
 
3. Assess the impact of intratumoral CD39+ Treg on cumulative 
relapse-free survival and cumulative cancer-specific survival in 
colon adenocarcinoma patients.  
 
4. Determine the presence and effector functions of MAIT cells in 
colon adenocarcinomas.  
 
5. Assess the impact of intratumoral MAIT cell infiltration on 
patient outcome in colon adenocarcinoma. 
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3 MATERIAL AND METHODS 
Patients, volunteers, and sample collection 
All studies included in the thesis were performed with the permission of the 
Regional Research Committee of West Sweden, and informed consent was given 
by all included patients. Only patients that had not received radiotherapy or 
chemotherapy for 3 years prior to surgery, and had no autoimmune diseases were 
included. Tissue material was obtained from patients undergoing curative 
resection of colon adenocarcinomas, and in part also from healthy blood donors. 
Heparinized venous blood was collected from the patients during surgery and 
biopsies of colon tumors and macroscopically normal appearing colon mucosa 
(unaffected colon tissue) was collected from the tumor resectate post-surgery. 
Tumor biopsies were representative of both central and peripheral parts of the 
tumor and unaffected colon tissue was taken > 10 cm from the tumor margin. 
Smaller biopsies were placed in RNA-later for 24 hours before freezing in -80 °C 
and subsequent RNA-extraction. Remaining tissue was placed in ice-cold PBS for 
less than 2 hours before cell isolation. Information of tumor stage, tumor 
differentiation grade, localization and metastases, was retrieved from the 
pathology report post-surgery.  
Isolation and stimulation of lymphocytes 
Pre-washed biopsies of colon tumor and unaffected colon tissue were cut into 5-
mm small tissue pieces and subjected to EDTA-buffer four times to remove the 
intraepithelial cell fraction. Intraepithelial lymphocytes (iELs) were saved from 
the second and third fractions, and the remaining tissue was further processed by 
enzymatic digestion (with Liberase and DNase) to obtain lamina propria 
lymphocytes (LPLs). Peripheral blood mononuclear cells (PBMCs), on the other 
hand, were isolated by Ficoll-Paque density-gradient centrifugation. Isolated 
lymphocytes were stimulated with PMA and ionomycin for approximately 10 
hours, i.e. a polyclonal stimulation which activates lymphocytes independently of  
TCR engagement, or with manufactured IL-12 and IL-18, two cytokines 
commonly secreted by macrophages in response to antigen and capable of 
inducing cell-mediated immunity. Golgi-stop was added 4-12 hours before 
harvesting, in order to halt the cytokine secretion of stimulated cells in due time 
prior to flow cytometric analysis.  
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Flow cytometry analyses and flow cytometry cell sorting 
Single cells isolated from peripheral blood, tumor, and unaffected colon tissue of 
colon adenocarcinoma patients, and PBMCs isolated from buffycoats of healthy 
donors, were stained with Live/dead aqua to exclude dead cells and at a later stage 
with a cocktail of antibody-fluorochrome conjugates in a one (extracellular 
staining) or two step (intracellular staining) process to detect marker expression. 
Foxp3 Staining Buffer Set was used for intracellular staining. FMO (fluorescence 
minus one) and isotype controls were run for reference to detect marker 
expression. Samples were run on an LSRII equipped with FACS DIVA software, 
which has three lasers (red, blue, violet) and allows for marker detection of up to 
approximately ten markers. Data was analyzed using Flow Jo software. Treg were 
identified as CD4+CD25hiFoxp3+ Treg (for phenotype experiments) and 
CD4+CD127lowCD25hi Treg (for functional experiments). Treg and conventional 
CD4+ T cells were sorted using a FACSAria. Sorted cells were manually counted 
with trypan blue and viability was 94% for Treg and 92% for conventional T cells. 
MAIT cells were identified as CD45+CD8+CD4-TCRyd-Va7.2+CD161high or as 
CD45+CD8+CD4- stained with MR1 tetramer loaded with 5-(2-
oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU). 
Suppression assay and cytokine analysis 
Single cells were isolated from buffycoat or tissue from colon adenocarcinoma 
patients. Buffycoats were pre-enriched for CD4+ T cells. Monocytes were enriched 
from CD4+ T cells using bead based separation, and seeded onto the 96-well plate 
(20000/well). Remaning isolated cells were stained and sorted. Conventional Treg 
(10000) and CD4+ T cells (10000), were seeded onto the plate, in different ratios 
of Treg:responder T cells, and stimulated with anti-CD3, and cells were harvested 
after four days in culture. In some experiments Treg were pre-stained with Far Red 
prior to culture. Upon harvesting cell proliferation was assessed by thymidine 
incorporation or analyzed by flow cytometry (experiments with Far Red stain). In 
addition, supernatants were collected after 2 days of culture and cytokine secretion 
was analyzed using a luminescence bead-based technique (the MAGPIX system). 
MSS/MSI analysis 
The microsatellite status of each colon tumor was analyzed through detection and 
qualitative assessment of amplified and fluorescently labeled microsatellite 
markers using the MSI Analysis System, Version 1.2 (ProMega). In total seven 
markers were co-amplified using PCR-based technique, including five 
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mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-
27) and two pentanucleotide repeat markers (Penta C and Penta D). Upon 
completion of the PCR-part of the assay, co-amplicons were detected on the ABI 
PRISM® 3730 using PowerPlex 4C Matrix Standard (Cat.# DG4800), according 
to the manufacturer’s instructions. Microsatellite instability, defined as peak 
alterations in the dinucleotide repeats of each microsatellite marker, was assessed 
using the marker electropherogram of the tumor compared to corresponding 
unaffected colon tissue. Tumors were defined as MSI-H tumors (if > 1 of the 5 
markers showed instability), MSI-L tumors (if only 1 marker showed instability) 
or MSS tumors (if no MSI was detected), and were analyzed using Peak scanner 
Software 2.  
Survival analysis 
Of patients selected to participate in the two survival analyses studies, the same 
basal inclusion criteria applied as for the patients included in the other studies. In 
addition, patients with non-radical surgery, non-primary tumors, or diagnosed 
rectal cancer, were also excluded from the studies. Patients characterized as stage 
IV were excluded from the relapse-free survival analysis but included in the 
cancer-specific survival analysis. Several patients were censored due to non-
cancer related death but remained in the study until they were censored. Estimated 
survivor curves were performed using the Kaplan-Meier method.  
Statistical methods 
Wilcoxon matched-pairs signed rank test was used to compare data obtained from 
the same patients. Mann-Whitney test and Kruskal-Wallis test were used to 
compare data obtained from different patients, between two groups and more than 
two groups, respectively. Correlation analysis was performed using nonparametric 
Spearman correlation. The Log-Rank test was used to compare Kaplan-Meier 
curves. P values of < 0.05 were considered significant. 
Regulatory T cells and mucosal-associated invariant T cells in colon adenocarcinomas; 
Phenotype and function 
 36 
Filip Ahlmanner 
 37 
4 KEY FINDINGS AND DISCUSSION 
4.1 PAPER I AND II 
An enrichment of CD39+ Treg have previously been observed in tumors of colon 
adenocarcinoma patients 198-200, and based on the attributed functions of CD39 expression by 
Treg in both cancer and other settings in vitro 196,201, we speculated that CD39+ Treg in colon 
tumors may be a superior immunosuppressive subset compared to other intratumoral Treg 
subsets. If so, CD39+ Treg would potentially be a major regulator of tumor immunity in colon 
cancer, due to their high numbers in the tumors. Further substantiating this hypothesis, a recent 
study by our group showed that Treg from colon cancer patients were able to inhibit the 
transendothelial migration of conventional effector T cells in vitro 198, accounting for a potential 
additional mechanism of suppression by CD39+ Treg in colon tumors. This effect was 
dependent on CD39-activity by Treg and an effect of adenosine on monocytes which in turn 
acted on endothelial cells.  
To test our hypothesis, we first characterized CD39+ Treg in colon cancer patients using flow 
cytometry. Also in our material Treg were enriched in the tumors (Paper I), and the majority of 
Treg also expressed CD39 on their surface. Furthermore, CD39 expression was higher among 
intratumoral Treg compared to Treg from both unaffected colon tissue and peripheral blood 
(Figure 7, left graph).  
 
Figure 7. Frequencies of CD39+ Treg in colon adenocarcinoma patients, and MFI of 
Foxp3 expression by CD39+ and CD39- Treg. 
At this stage, after having confirmed previous findings 198-200, we wanted to further characterize 
intratumoral CD39+ Treg ex vivo with regard to established and functionally important Treg 
effector molecules in other settings and diseases.  We did this by comparing marker expression 
between CD39+ and CD39- Treg in the tissues;  in Treg isolated from colon tumors, unaffected 
colon tissue and peripheral blood. CD39 expression by Treg had previously been correlated 
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with an upregulated FoxP3 expression 186, and we therefore first analyzed Foxp3-expression 
within the respective subsets. Interestingly, mean fluoresence intensity (MFI) of Foxp3, i.e. 
mean level of Foxp3 expression per cell, was significantly higher in CD39+ Treg compared to 
CD39- Treg in all three tissues. (Figure 7, right graph).  
In light of this finding we were curious to investigate if a high expression of Foxp3 would 
potentially drive further upregulation of other established Treg markers and effector molecules 
in the CD39+ Treg subset.  Indeed, using the same methodology to compare marker expression 
between CD39+ and CD39- Treg intra tissue, we found a higher expression of several  
immunosuppressive effector molecules, such as PD-L1 and CTLA-4, in the intratumoral 
CD39+ Treg subset (Paper I, Figure 3). Furthermore, CD39+ Treg in the tumor proliferated more 
compared to CD39- Treg as measured by Ki67 expression, and CD39+ Treg also had a higher 
expression of the co-stimulatory marker ICOS indicating a higher level of activation in this 
subset (Paper 1). In conclusion, this phenotypic data suggests that CD39+ Treg are a highly 
immunosuppressive Treg subset in colon tumors.  
So far, the phenotypic data on intratumoral CD39+ Treg supported our stated hypothesis, but we 
had not yet confirmed this in functional experiments. Although unlikely, CD39- Treg could for 
example constitute a more stable subset or have a higher expression of other suppressive 
markers which we had not included in our phenotypic analysis, thus balancing the presumed 
difference in suppressive ability between the subsets. To investigate the function of CD39+ Treg 
we first performed suppression assay experiments in vitro using peripheral blood of healthy 
donors. While this suppression assay system, further explained in the methodology section of 
the thesis, was optimized to measure proliferative responses, it also allowed us to assess cytokine 
production in the co-cultures. However, detected cytokine levels were low and, in cultures of 
peripheral blood, only IFN-g production by conventional CD4+ T  cells (responder T cells), was 
reproducibly suppressed by both CD39+ and CD39- autologous Treg, when these were added 
to the cultures (Paper I, Figure 6). In the same cultures, suppressive effect by Treg on responder 
T cell proliferation was however easier detected, and both Treg subsets were clearly suppressive 
in this regard (Figure 8, left graph). In the cultures where CD39+ Treg were added to the 
responder T cells we found lower levels of remaining proliferation compared to the 
corresponding cultures with CD39- Treg (Figure 8, left graph). However, these experiments 
were based on thymidine incorporation measurements and consequently reflected total 
proliferation levels in the cultures. Since also the different Treg subsets potentially could 
proliferate in the presence of IL-2 produced by responder T cells, we could not be certain that 
these initial findings accounted for an isolated suppressive effect by Treg on autologous 
responder T cells. This effect is presumably not dependent on our in vitro system and also 
previous studies that have measured suppression by Treg using thymidine incorporation should 
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have encountered similar problems. Consequently, both CD39+ and CD39- Treg isolated from 
peripheral blood of healthy donors, potently suppress autologous responder T cells in vitro 
(Figure 8, left graph), but we could not determine difference in suppressive ability between the 
two subsets at this stage. Also, in this in vitro system, Treg isolated from colon tumors were 
highly immunosuppressive, but independent of CD39 expression, which confirms previous 
findings (Paper I, Suppl. Figure 7). 
 
Figure 8. Effect of CD39+ and CD39- Treg on conventional CD4+ T cell 
proliferation, and dynamics of CD39+ and CD39- Treg during culture. 
To determine the dynamics of CD39+ and CD39- Treg in the co-cultures, we 
stained both Treg subsets with Celltrace Far Red prior to adding them to the 
responder T cells. Upon harvesting, we were thus able to differentiate between 
responder T cells and Far Red+ Treg using flow cytometry, and Celltrace Far Red 
also allowed us to determine proliferative response in each Treg subset (Figure 8, 
right graph). Somewhat surprisingly, we observed a significant upregulation of 
CD39 expression in the sorted original CD39- Treg subset (Figure 8, right graph). 
This was in contrast to previous control experiments when we stimulated total 
PBMCs with PMA/Ionomycin and detected only a modest upregulation of CD39 
by Treg. Consequently, an upregulation of CD39 in the original CD39- Treg subset 
during culture, led us to conclude that it would be almost impossible to compare 
suppressive ability between CD39+ and CD39- Treg in vitro. However, these 
experiments allowed us to compare proliferative response of the different Treg 
subsets during culture; on the one hand sorted CD39+ Treg and on the other hand 
sorted original CD39- Treg which either remained CD39- or upregulated CD39 
during culture (converted CD39+ Treg). By clustering Far Red+ cells into different 
populations based on fluorescence intensity (a proportionally lower intensity the 
more times a cell has divided), we were able to determine degree of cell division 
within each Treg subsets. Interestingly, the replication index, i.e. the fold 
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expansion of only the responding cells, showed that converted CD39+ Treg had 
the highest proliferation of all three subsets (Paper I).  
In Paper II we wanted to correlate CD39 expression by intratumoral Treg in colon 
cancer with patient outcome. A correlation between high levels of intratumoral 
Treg and a less favorable patient outcome, has been found in some studies 244-246, 
and since intratumoral Treg generally are believed to suppress anti-tumor 
immunity by inhibiting effector T cells, this would be an alternative approach to 
test the hypothesis that intratumoral CD39+ Treg have superior suppressive ability 
and thus presumably a negative impact on patient outcome.  
To broaden our knowledge of intratumoral CD39+ Treg, we first investigated the 
inter tissue relationship of CD39 expression by Treg in colon cancer patients. 
Interestingly, there was a positive correlation between frequencies of intratumoral 
CD39+ Treg and CD39+ Treg frequencies in both peripheral blood and unaffected 
colon tissue (Figure 9). In addition to the potential interest from a prognostic 
biomarker perspective, this suggests that intratumoral CD39+ Treg levels are in 
part dependent on peripheral blood CD39+ Treg which may supply the tumor site 
with new CD39+ Treg. 
 
Figure 9. Correlation between CD39 expression by Treg in different tissues.  
It was clear from the data obtained in paper I that colon tumors divide into two 
populations based on the frequency of CD39-expressing Treg among total 
intratumoral Treg (Figure 7, left graph). We suggest that this division reflects 
differences in either tumor characteristics or individual differences in the immune 
response towards the tumor. Consequently, we used this already existing 
difference between patient groups to stratify colon cancer tumors into two types, 
i.e. group I and II tumors with high (> 75%) and low (< 75%) frequencies of CD39-
expressing Treg among total intratumoral Treg, respectively (Figure 10, FACS-
plots). We also referred to these two patient groups as population I (group I tumors) 
and population II (group II tumors).  
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Figure 10. CD39 expression by Treg from colon adenocarcinoma patients, and 
frequencies of intratumoral CD39+ Treg in relation to microsatellite status and 
clinical parameters.   
As a first step to investigate the contribution of intratumoral CD39+ Treg to patient 
prognosis, we analyzed group I and II tumors in relation to prognostically 
important clinical parameters in colon cancer 4,40,55. Since MSI-H tumors are 
associated with a stronger immune activation compared to MSS tumors, and also 
a more favorable patient outcome 44, we were particularly interested in determining 
a role of intratumoral CD39+ Treg in this context. However, there was no 
relationship between tumor microsatellite status and CD39 expression by 
intratumoral Treg (Figure 10, above graph), and presumably a strong immune 
activation within MSI-H tumors cannot be explained by a low number of CD39+ 
Treg in those tumors. Also, there was no significant relationship between CD39 
expression by intratumoral Treg and any of the other variables analyzed, and group 
I and II tumors seemed evenly distributed between groups when analyzed in 
relation to T stage, lymph node spread and tumor stage (Figure 10, lower graphs).  
We then compared cumulative cancer-specific survival and cumulative relapse-
free survival between group I and II colon tumors (population I and II, 
respectively). This survival analysis is explained further in the methodology 
section of the thesis. Based on previous findings with regard to phenotype and 
presumed function of intratumoral CD39+ Treg in colon tumors, we speculated 
that patients belonging to population I would have a higher degree of 
immunosuppression in the tumors and consequently a less favorable patient 
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outcome. Preliminary survival data also pointed in this direction, and especially 
with regard to cumulative cancer-specific survival, as cumulative relapse-free 
survival was more similar between groups when comparing Kaplan-Meier curves 
(Figure 11).  
 
Figure 11. Frequencies of intratumoral CD39+ Treg and patient outcome.  
With the relatively low number of events detected so far in the sample this 
difference was however not significant but a lower cumulative cancer-specific 
survival in population I compared to population II, may possibly substantiate the 
presence of functionally diverse intratumoral Treg subsets in colon cancer. 
Additional patient events (from death or relapse), which will likely follow upon 
added follow-up time, are required in order to conduct multivariate analysis to 
investigate if CD39 expression by intratumoral Treg, also is an independent 
predictor of survival in colon cancer patients.  
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4.2 PAPER III AND APPENDIX 
In paper III and Appendix, we studied MAIT cells in colon adenocarcinomas, a 
subset of innate-like T cells, present at the tumor site. MAIT cells are believed to 
provide a first line defense towards intestinal microbes and since colon tumors are 
associated with both epithelial barrier breach and an increased infiltration of 
microbes 111, MAIT cell presence at the tumor site should be expected. MAIT cells 
were identified as CD45+CD3+CD4-TCRgd-CD161highVa7.2+ cells or by tetramer 
staining of CD45+CD3+CD4- cells using MR1 tetramer loaded with 5-OP-RU. In 
paper III we were one of the first to show an accumulation of MAIT cells in colon 
tumors compared to unaffected colon tissue (Paper III, Figure 2), and we also 
confirm this in a separate patient cohort (Figure 12, left graph), where we studied 
the impact of intratumoral MAIT cells on patient survival in colon cancer 
(Appendix). In the same patient cohort (Appendix), we also detected a positive 
correlation (p < 0.0001) between frequencies of circulating MAIT cells and 
intratumoral MAIT cell frequencies (Figure 12, right graph). This suggests that 
frequencies of circulating MAIT cells in colon cancer patients may serve as a 
predictor of intratumoral MAIT cell frequencies, but it may also suggest that colon 
cancer affects the circulating pool of MAIT cells to a lower degree compared to 
inflammatory bowel disease (IBD) and autoimmune diseases 215,216. Indeed, 
frequencies of MAIT cells isolated from peripheral blood of colon cancer patients 
were equal to those of healthy controls (Paper III, Figure 1B), while frequencies 
of MAIT cells in peripheral blood of multiple sclerosis and IBD patients were 
lower in affected patients 215,216.  
 
Figure 12. Frequencies of MAIT cells in colon adenocarcinoma patients, and 
correlation between circulating and intratumoral MAIT cell frequencies.  
It has been shown that MAIT cells in the colonic lamina propria are dominated by 
a Th1 phenotype, but in other contexts MAIT cells can also produce Th17 
associated cytokines. To investigate the context dependent function of 
intratumoral MAIT cells in colon cancer, with regard to cytokine secretion, we 
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stimulated MAIT cells with PMA and ionomycin ex vivo. Also intratumoral MAIT 
cells in colon cancer were dominated by a Th1 phenotype (with IFN-g and TNF-a 
production; Paper III, Figure 3). Interestingly, the frequencies of IFN-g-producing 
MAIT cells was lower in colon tumors compared to unaffected colon tissue 
(Figure 13, left graph), while IL-17 production in this context was produced by 
few cells irrespective of tissue origin (Figure 13, right graph). 
 
Figure 13. Cytokine production of IFN-g and IL-17 by MAIT cells in colon 
adenocarcinoma patients.  
High infiltration of MAIT cells in colon tumors have previously been associated 
with a less favorable prognosis in colon cancer 247 and we performed a similar 
survival analysis also in our patient cohort to examine this further. However, in 
contrast to the result obtained by Zabijak et al., we found the opposite result in our 
preliminary survival data, with a higher cumulative relapse-free survival in the 
patient group with high MAIT cell infiltration in colon tumors when the sample 
was stratified according to the above and lower quartile values of intratumoral 
MAIT cell frequencies (Figure 14, left graph). Cumulative cancer-specific 
survival was more similar between groups (Figure 14, right graph). 
 
Figure 14. Frequencies of intratumoral MAIT cells and patient outcome. 
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5 CONCLUSION AND FUTURE PERSPECTIVES 
To conclude from Paper I and II, we confirm an accumulation of Treg in colon 
adenocarcinomas and a high immunosuppressive ability of this subset on 
responder T cell proliferation in vitro is potentially a result of high levels of CD39+ 
Treg among total intratumoral Treg. Indeed, similar to CD39+ Treg isolated from 
peripheral blood, which are highly immunosuppressive in vitro, CD39+ Treg in 
colon tumors express markers of increased suppressive function. In addition, 
intratumoral CD39+ Treg also proliferated more compared to CD39- Treg as 
measured by Ki67 expression ex vivo, and a similar observation was made by flow 
cytometry in Treg isolated from peripheral blood with regard to converted CD39+ 
Treg which displayed a superior proliferative response. These findings suggest that 
CD39+ Treg are a highly immunosuppressive Treg subset in colon tumors and 
interestingly, CD39+ Treg possess several phenotypic similarities with putative 
CD4+CD45RA-CD25+++Foxp3hi activated or memory Treg, as characterized by 
Miyara et al. in peripheral blood 163, and more recently correlated to a less 
favorable patient outcome in CRC patients 248. So far, immunosuppressive ability 
of intratumoral CD39+ Treg in colon cancer has not been directly linked to CD39-
activity, as it has in breast cancer where an anti-CD39 antibody released the 
suppressive effect of Treg on IFN-g production by Th1 and CD8+ T cells 196. The 
survival analysis in paper II is at this stage somewhat preliminary but at least there 
is a clear trend towards a lower cancer-specific survival in patients with high 
accumulation of intratumoral CD39+ Treg. This is promising data and it remains 
to be established if CD39+ Treg could serve as a potential future target of cancer 
immunotherapy in colon cancer.  
To conclude from paper III and appendix, a high MAIT cell infiltration in colon 
tumors has previously been correlated to a less favorable patient prognosis which 
is in direct contrast to our preliminary survival data. It is curious why MAIT cells, 
dominated by a Th1 phenotype in colon cancer, would be associated with a less 
favorable patient prognosis. This is in contrast to colon tumors with high 
infiltration of Th 1 cells. Additional studies are needed to clarify the impact of 
intratumoral MAIT cells in colon cancer, especially with regard to their effector 
functions.
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